Enhanced Liver Fibrosis (ELF™) Test
Siemens Healthineers offers the ELF test to help improve the assessment of NAFLD/NASH and chronic liver disease patients at risk of disease progression.
The ELF Test* is a non-invasive blood test that measures three direct markers of fibrosis: hyaluronic acid (HA), procollagen III amino-terminal peptide (PIIINP), and tissue inhibitor of matrix metalloproteinase 1 (TIMP-1). The ELF Test, in conjunction with other laboratory and clinical findings, can be used to assess the risk of progression to cirrhosis and liver-related clinical events (LREs) in patients with chronic liver disease.
- Access non-invasive testing with a simple blood test available to all healthcare practitioners and patients, including those with type 2 diabetes mellitus and obesity.
- Improve patient care by identifying non-alcoholic fatty liver disease (NAFLD) patients and stratifying those at risk of progressing to cirrhosis and LREs.
- Enhance prognostic patient management with a test that has been shown to outperform biopsy for the risk assessment of progression to cirrhosis and LREs.
*The ELF™ Test kit is under development in the U.S. Product availability varies by country.The ELF Testing Service is available from Siemens Healthcare Laboratory, a CLIA-certified laboratory located in Berkeley, CA.